Your browser doesn't support javascript.
loading
MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia.
Wu, Bian; Slabicki, Mikolaj; Sellner, Leopold; Dietrich, Sascha; Liu, Xiyang; Jethwa, Alexander; Hüllein, Jennifer; Walther, Tatjana; Wagner, Lena; Huang, Zhiqin; Zapatka, Marc; Zenz, Thorsten.
Afiliação
  • Wu B; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Slabicki M; Molecular Therapy in Haematology and Oncology & Department of Translational Oncology, National Centre for Tumour Disease (NCT) and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Sellner L; Molecular Therapy in Haematology and Oncology & Department of Translational Oncology, National Centre for Tumour Disease (NCT) and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Dietrich S; Molecular Therapy in Haematology and Oncology & Department of Translational Oncology, National Centre for Tumour Disease (NCT) and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Liu X; Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Jethwa A; Molecular Therapy in Haematology and Oncology & Department of Translational Oncology, National Centre for Tumour Disease (NCT) and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Hüllein J; Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Walther T; Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.
  • Wagner L; Molecular Therapy in Haematology and Oncology & Department of Translational Oncology, National Centre for Tumour Disease (NCT) and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Huang Z; Molecular Therapy in Haematology and Oncology & Department of Translational Oncology, National Centre for Tumour Disease (NCT) and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Zapatka M; Molecular Therapy in Haematology and Oncology & Department of Translational Oncology, National Centre for Tumour Disease (NCT) and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Zenz T; Molecular Therapy in Haematology and Oncology & Department of Translational Oncology, National Centre for Tumour Disease (NCT) and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
Br J Haematol ; 179(3): 421-429, 2017 11.
Article em En | MEDLINE | ID: mdl-28771672
ABSTRACT
Mutations in the N-terminus of MED12 protein occur at high frequency in uterine leiomyomas and breast fibroepithelial tumours, and are frequently found in chronic lymphocytic leukaemia (CLL). MED12 mutations have been previously linked to aberrant Cyclin C-CDK8 kinase activity, but the exact oncogenic function in CLL is unknown. Here, we characterized MED12 mutations in CLL and identified recurrent mutations in 13 out of 188 CLL patients (6·9%), which clustered in the N-terminus. MED12 mutations were associated with unmutated IGHV (P = 0·024). Protein analysis of NOTCH1 in primary CLL samples revealed increased levels of NOTCH1 intracellular domain (NICD), the active form of NOTCH1, in the context of MED12 mutations. We found evidence that NICD is the target of Cyclin C-CDK8 kinase using a specific CDK8 inhibitor. In line with these findings, MED12 mutations were mutually exclusive to mutations in NOTCH1 in CLL, based on a meta-analysis of 1429 CLL patients (P = 0·011). Our results suggest that MED12 mutations may contribute to CLL pathogenesis by activating NOTCH signalling.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Receptor Notch1 / Complexo Mediador / Mutação Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Receptor Notch1 / Complexo Mediador / Mutação Idioma: En Ano de publicação: 2017 Tipo de documento: Article